{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:02:49Z","timestamp":1790420569152,"version":"4.1.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T00:00:00Z","timestamp":1496361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7,1]]},"abstract":"<jats:p>With the Breakthrough Therapy Designation program adding to the tools that the U.S. Food and Drug Administration (FDA) has for expediting drug development, the FDA reassessed the endpoints needed for approval of transformative therapies. Although the demonstration of an improvement in overall survival remains the gold standard for drug approval, innovation in cancer research has led to use of other endpoints in regulatory decision-making. These endpoints include substantially delaying tumor progression or extending progression-free survival, substantially reducing tumor size for a prolonged time, improving objective response rate and duration of response, or improving cancer-related symptoms and patient function.<\/jats:p>","DOI":"10.1634\/theoncologist.2017-0152","type":"journal-article","created":{"date-parts":[[2017,6,3]],"date-time":"2017-06-03T00:10:24Z","timestamp":1496448624000},"page":"762-767","source":"Crossref","is-referenced-by-count":68,"title":["Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies"],"prefix":"10.1093","volume":"22","author":[{"given":"Gideon M.","family":"Blumenthal","sequence":"first","affiliation":[{"name":"Office of Hematology Oncology Products, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Kluetz","sequence":"additional","affiliation":[{"name":"Office of Hematology Oncology Products, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Schneider","sequence":"additional","affiliation":[{"name":"Office of Hematology Oncology Products, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten B.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Office of Hematology Oncology Products, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"McKee","sequence":"additional","affiliation":[{"name":"Office of Hematology Oncology Products, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Pazdur","sequence":"additional","affiliation":[{"name":"Office of Hematology Oncology Products, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Silver Spring, Maryland, USA"},{"name":"Oncology Center of Excellence U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,6,2]]},"reference":[{"key":"2021122508123730500_onco12182-bib-0001","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMp1311439","article-title":"Expediting drug development\u2014The FDA's new \u201cbreakthrough therapy\u201d designation","volume":"369","author":"Sherman","year":"2013","journal-title":"N Engl J Med"},{"key":"2021122508123730500_onco12182-bib-0002","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nrd.2016.19","article-title":"Regulatory Watch: Impact of breakthrough therapy designation on cancer drug development","volume":"15","author":"Shea","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"2021122508123730500_onco12182-bib-0003","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1634\/theoncologist.13-S2-19","article-title":"Endpoints for assessing drug activity in clinical trials","volume":"13","author":"Pazdur","year":"2008","journal-title":"The Oncologist"},{"key":"2021122508123730500_onco12182-bib-0004","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122508123730500_onco12182-bib-0005","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/0003-4819-87-3-293","article-title":"Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer","volume":"87","author":"Einhorn","year":"1977","journal-title":"Ann Intern Med"},{"key":"2021122508123730500_onco12182-bib-0006","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMra1407550","article-title":"Testicular cancer\u2014Discoveries and updates","volume":"371","author":"Hanna","year":"2014","journal-title":"N Engl J Med"},{"key":"2021122508123730500_onco12182-bib-0007","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1634\/theoncologist.7-5-390","article-title":"for the treatment of chronic myelogenous leukemia: U.S. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status","volume":"7","author":"Cohen","year":"2002","journal-title":"The Oncologist"},{"key":"2021122508123730500_onco12182-bib-0008","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122508123730500_onco12182-bib-0009","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"2021122508123730500_onco12182-bib-0010","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1158\/1078-0432.CCR-13-3077","article-title":"U.S. Food and Drug Administration approval: Crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive","volume":"20","author":"Malik","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2021122508123730500_onco12182-bib-0011","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1634\/theoncologist.2014-0241","article-title":"FDA approval summary: Crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements","volume":"19","author":"Kazandjian","year":"2014","journal-title":"The Oncologist"},{"key":"2021122508123730500_onco12182-bib-0012","year":"2011"},{"key":"2021122508123730500_onco12182-bib-0013","year":"2017"},{"key":"2021122508123730500_onco12182-bib-0014","year":"2017"},{"key":"2021122508123730500_onco12182-bib-0015","year":"2017"},{"key":"2021122508123730500_onco12182-bib-0016","year":"2017"},{"key":"2021122508123730500_onco12182-bib-0017","year":"2017"},{"key":"2021122508123730500_onco12182-bib-0018","year":"2017"},{"key":"2021122508123730500_onco12182-bib-0019","year":"2017"},{"key":"2021122508123730500_onco12182-bib-0020","year":"2017"},{"key":"2021122508123730500_onco12182-bib-0021","year":"2017"},{"key":"2021122508123730500_onco12182-bib-0022","year":"2017"},{"key":"2021122508123730500_onco12182-bib-0023","year":"2017"},{"key":"2021122508123730500_onco12182-bib-0024","year":"2017"},{"key":"2021122508123730500_onco12182-bib-0025","year":"2017"},{"key":"2021122508123730500_onco12182-bib-0026","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1001\/jamaoncol.2015.6352","article-title":"Response rate as an approval end point in oncology: Back to the future","volume":"2","author":"Blumenthal","year":"2016","journal-title":"JAMA Oncol"},{"key":"2021122508123730500_onco12182-bib-0027","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1093\/annonc\/mdt358","article-title":"Equipoise abandoned? Randomization and clinical trials","volume":"24","author":"Kurzrock","year":"2013","journal-title":"Ann Oncol"},{"key":"2021122508123730500_onco12182-bib-0028","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/cpt.86","article-title":"The role of nonrandomized trials in the evaluation of oncology drugs","volume":"97","author":"Simon","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"2021122508123730500_onco12182-bib-0029","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1200\/JCO.2014.59.0489","article-title":"Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses","volume":"33","author":"Blumenthal","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122508123730500_onco12182-bib-0030","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"2021122508123730500_onco12182-bib-0031","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122508123730500_onco12182-bib-0032","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"2021122508123730500_onco12182-bib-0033"},{"key":"2021122508123730500_onco12182-bib-0034","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1158\/1078-0432.CCR-12-0653","article-title":"U.S. Food and Drug Administration approval: Ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis","volume":"18","author":"Deisseroth","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021122508123730500_onco12182-bib-0035","first-page":"1553","article-title":"Focusing on patient-reported outcomes in cancer clinical trials: Symptomatic adverse events, physical function, and disease-related symptoms. Clin Cancer","volume":"22","author":"Kluetz","year":"2016","journal-title":"Res"},{"key":"2021122508123730500_onco12182-bib-0036","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122508123730500_onco12182-bib-0037","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"2021122508123730500_onco12182-bib-0038","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.e19536","article-title":"Impact of novel therapies on multiple myeloma survival in the US: Current and future outcomes","author":"Drawid","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122508123730500_onco12182-bib-0039","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamaoncol.2015.1790","article-title":"Colorectal survival gains and novel treatment regimens: A systemic review and analysis","volume":"1","author":"Jawad","year":"2015","journal-title":"JAMA Oncol"},{"key":"2021122508123730500_onco12182-bib-0040","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1200\/JCO.2008.20.5278","article-title":"Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy","volume":"27","author":"Kopetz","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122508123730500_onco12182-bib-0041","author":"Lowes"},{"key":"2021122508123730500_onco12182-bib-0042"},{"key":"2021122508123730500_onco12182-bib-0043","author":"Nelson"},{"key":"2021122508123730500_onco12182-bib-0044","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1634\/theoncologist.2014-0089","article-title":"U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations","volume":"19","author":"Khozin","year":"2014","journal-title":"The Oncologist"},{"key":"2021122508123730500_onco12182-bib-0045","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1158\/1078-0432.CCR-15-2266","article-title":"FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer","volume":"22","author":"Kazandjian","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2021122508123730500_onco12182-bib-0046","author":"Stenger"},{"key":"2021122508123730500_onco12182-bib-0047","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1634\/theoncologist.2014-0143","article-title":"Approval after phase 1: Ceritinib runs the three-minute mile","volume":"19","author":"Chabner","year":"2014","journal-title":"The Oncologist"},{"key":"2021122508123730500_onco12182-bib-0048","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMp1603747","article-title":"Seamless oncology-drug development","volume":"374","author":"Prowell","year":"2016","journal-title":"N Engl J Med"},{"key":"2021122508123730500_onco12182-bib-0049","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence\u2014What is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N Engl J Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0152","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0152","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/7\/762\/41916010\/oncolo_22_7_762.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/7\/762\/41916010\/oncolo_22_7_762.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T08:13:20Z","timestamp":1640420000000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/22\/7\/762\/6444385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,2]]},"references-count":49,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,6,2]]},"published-print":{"date-parts":[[2017,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0152","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,7,1]]},"published":{"date-parts":[[2017,6,2]]}}}